SciELO - Scientific Electronic Library Online

 
vol.34 issue2Quality control of enteral nutrition therapy in cancer patients at nutritional riskOral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass. A randomized clinical trial author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Nutrición Hospitalaria

On-line version ISSN 1699-5198Print version ISSN 0212-1611

Abstract

BURGOS-PELAEZ, Rosa et al. Cost analysis of home parenteral nutrition in Spain. Nutr. Hosp. [online]. 2017, vol.34, n.2, pp.271-276. ISSN 1699-5198.  http://dx.doi.org/10.20960/nh.705.

Introduction:

Home parenteral nutrition (HPN) improves quality of life, allowing patients to receive nutrition at home and providing a social and labor integration to these patients.

Objective:

To assess the direct costs of HPN in adult population in Spain.

Methods:

A literature review of the records of HPN in Spain, carry out by NADYA-SENPE Group (years 2007-2014), was performed. The analysis included the evolution of: patients requiring HPN, number of episodes/patient, mean duration of episodes, description of delivery routes and complications rate. HPN consumption and cost were estimated. Patients were grouped according to their pathological group: benign and malignant. Direct costs (€, 2015) included were: parenteral nutrition bags, delivery sets and costs due to complications.

Results:

The number of patients who receive HPN has increased over years (2007: 133 patients; 2014: 220 patients). The average number of episodes per patient ranged from 1-2 episodes per year. The average duration of those episodes decreased (2007: 323 days; 2014: 202.8 days). Tunneled catheters were the most used and septic complications were the most common. The average annual cost per patient was estimated at € 8,393.30 and € 9,261.60 for benign and malign disease respectively. Considering that 220 patients required HPN in 2014, an annual cost of € 1,846.524.96 (€ 1,389,910.55 directly due to HPN) and € 2,037,551.90 (€ 1,580,937.50 directly due to HPN) was estimated for patients with benign and malignant pathologies respectively.

Conclusions:

These results can be used to develop future economic evaluations on HPN and to establish efficient prioritization strategies to allocate available resources.

Keywords : Home parenteral nutrition; Complications; Venous access; Cost analysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )